arrow
T

Toni Sarapohja

Heinrich-Heine-University Dusseldorf
H指数:18
被引数:2,953

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

从安慰剂到达鲁他胺的交叉对非转移性前列腺癌男性总生存期的影响: 来自ARAMIS随机3期研究的敏感性分析

2023-12-010
OA
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial

来自ARAMIS随机3期试验的达鲁柳胺对伴合并症和合并用药的非转移性去势抵抗性前列腺癌患者的疗效和安全性

2023-10-014
OA
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
2023-03-019
OA
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial (vol 83, pg 212, 2023)
2023-02-011
OA
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Darolutamide与非转移性去势抵抗性前列腺癌患者的健康相关生活质量: 对ARAMIS III期试验的分析

2021-09-0129
OA
Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy
2017-09-0122
OAAI